2026 AI Rules: Banks’ Compliance Survival Guidance
Learn Treasury’s 230-control FS AI RMF and key priorities for AI governance, human oversight, and compliance in financial institutions for 2026.
FCC Bans Foreign Drones: US Market Shift Looms
Understand FCC’s addition of all foreign-made UAS and critical components to Covered List: exemptions, compliance steps, business impacts, and US market shifts.
LRN Catalyst Cuts Phishing Risk 70% Via Behavior Shift
Learn how LRN Catalyst transforms employee behavior via AI-driven phishing simulations, cutting risk 70% while meeting NIST, NIS2 regulations.
EPA’s Compliance First Policy: Cut Penalties, Boost Business?
Discover how EPA’s Compliance First policy shifts enforcement to prioritize assistance over penalties, impacting business compliance strategies, risks, and operations.
Title 31 Fines Hit $75M: Public Records Save Casinos
Learn how public record intelligence enhances casino AML compliance, prevents Title 31 fines, strengthens KYC/EDD, and combats fraud risks.
FDA Eliminates Biosimilar Testing Requirements, Slashing Development Costs
Understand FDA’s Oct. 2025 biosimilar framework that eliminates efficacy studies and cuts $100M+ costs via analytics, streamlines interchangeability for faster market entry.
How Financial Firms Balance AI Speed With Audit Compliance
Discover how financial firms balance AI speed with audit compliance using auditable agentic workflows. Insights from Moody’s and Prudential on regulatory strategies, best practices, and scaling AI in credit and claims.
AI Hiring Tools Face Mounting Legal Risks in 2026
Learn AI hiring legal risks in 2026: bias lawsuits like Mobley v. Workday, FCRA claims vs. Eightfold, state laws, and compliance strategies for audits, vendor due diligence.
NEC 2023 updates strain aging electrical systems with smart tech – risking fines for property owners
Understand why NEC 2023 updates for surge protection, EV chargers, and IoT overload aging systems, risking fines for property owners. Learn compliance audits, upgrades, and steps to mitigate penalties.
FDA Warning Crushes ExThera Blood Filter Sales
Understand FDA’s warning letter to ExThera over Seraph 100 blood filter violations: unapproved marketing claims, compassionate use failures, and compliance steps for device makers.